CD274 and non-small cell lung carcinoma: The percentage of tumor cells (TC) with PD-L1 (Programmed Cell Death Ligand 1) expression is determined during the qualification of patients with advanced non-small cell lung cancer (NSCLC) to therapy with immune checkpoint inhibitors (ICIs) in monotherapy or combination with chemotherapy.